A worsened prognosis for patients after stroke with newly diagnosed atrial fibrillation compared to having a preexisting arrhythmia

与既往存在心律失常的患者相比,卒中后新诊断出房颤的患者预后更差。

阅读:1

Abstract

INTRODUCTION: Atrial fibrillation (AF) is a major cause of ischemic stroke. Patients with undiagnosed AF lack the stroke prevention provided by oral anticoagulants. The aim of this study was to compare the in-hospital mortality rate between ischemic stroke patients diagnosed with AF de novo and ischemic stroke patients diagnosed with AF prior to hospitalization for stroke. MATERIAL AND METHODS: We identified patients admitted to the Neurology Center during the years 2013-2014 with acute ischemic stroke and AF. We analyzed in-hospital outcomes in patients with newly diagnosed AF and those with known AF. The study endpoint was death during hospitalization. RESULTS: The study included 2,000 patients with acute ischemic stroke, out of whom 579 (29%) patients were diagnosed with AF. AF was newly diagnosed in 123 (21.2%) patients (new-AF group), while 456 (78.8%) patients had a history of AF (previous-AF group). The mean National Institutes of Health Stroke Scale (NIHSS) score at admission was 7.2 points in the new-AF group and 3.7 in the previous-AF group (p < 0.001). In-hospital death was more common in the new-AF group (13 patients, 10.6%) than in the previous-AF group (16 patients, 3.5%) (p = 0.003). In multivariate analysis, the NIHSS score at admission in the new-AF group was associated with higher mortality, while in the previous-AF group, the NIHSS score at admission and multiple ischemic foci were risk factors of in-hospital mortality. CONCLUSIONS: Newly diagnosed AF in ischemic stroke patients significantly worsens prognosis compared to patients previously diagnosed with AF. Early detection of latent AF and subsequent use of anticoagulation are important in preventing severe stroke.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。